Lotrimin AF Athlete's Foot Antifungal Powder with Miconazole Nitrate 2% - US Product Analysis

1. Product Information

Lotrimin AF Athlete's Foot Antifungal Powder is an over-the-counter medicated foot powder sold here as a three-bottle pack of 3 oz (90 g) shaker bottles, 9 oz of product in total. Its active ingredient is miconazole nitrate 2%, and the listing claims it is clinically proven to cure most athlete's foot (tinea pedis) while also treating jock itch and ringworm. The formulation is a starch-and-clay dry powder, so the product does two jobs at once: it delivers the antifungal and it absorbs the moisture that promotes fungal growth in the first place. The listing claims relief from the itching, burning and scaling of cracked skin on the feet and toes, and states it is safe for children over two.

The printed treatment course is specific: wash and dry the affected area, sprinkle a thin layer twice daily, pay special attention to the spaces between the toes, wear well-fitting ventilated shoes, and change shoes and socks at least once daily. Four weeks daily for athlete's foot and ringworm, two weeks daily for jock itch. The product is explicitly not effective on the scalp or nails. The listing dates to October 2020 and ranks 36th in Antifungal Remedies at capture.

1.1 Product Gallery

1.2 Specifications

1.3 Listing Highlights

• Provides relief — effectively relieves the discomfort of itchy, cracked skin on feet and toes.
• Treats to lower risk — treating athlete's foot lowers the risk of nail fungus.
• Proven to cure most athlete's foot — clinically proven to control the fungus that causes tinea pedis.
• Safe for kids over 2 — can easily get between tiny toes for fast relief, with supervision.
• Contains 2% miconazole nitrate — the clinically proven active that controls the fungus behind athlete's foot, jock itch and ringworm.
• Keeps feet dry — formulated to absorb sweat while it works, because moisture promotes fungal growth.

1.4 How the Brand Frames It (A+ Content)

The manufacturer's A+ block opens with a scale claim — that 70% of people experience athlete's foot at some point in their life — and frames cracked skin as a sign that the skin's natural barrier has been damaged, which may allow fungus to enter and cause an infection. Its argument is treat-then-prevent: use an antifungal to clear the infection, then continue with a prevention product to keep most athlete's foot from returning.

1.5 Usage and Safety Information

Directions. Wash the affected area and dry thoroughly. Sprinkle a thin layer over the affected area twice daily (morning and night). Supervise children in the use of this product. For athlete's foot, pay special attention to the spaces between the toes; wear well-fitting, ventilated shoes and change shoes and socks at least once daily. For athlete's foot and ringworm, use daily for 4 weeks; for jock itch, use daily for 2 weeks. If the condition persists longer, ask a doctor. This product is not effective on the scalp or nails. Store between 20° and 25°C (68° to 77°F).

Active ingredient. Miconazole nitrate 2%.

2. Product Rating and Customer Voice

The listing carries an aggregate rating of 4.7 out of 5 from 5,101 global ratings. The distribution is concentrated at the top with a heavier four-star shoulder than is typical: 81% five-star and 13% four-star, so 94% of raters sit at four stars or better. The negative tail is thin and flat — three-star at 4%, two-star at 1%, one-star at 1%.

2.1 Reading the Distribution

The four-star bucket at 13% is the notable feature: it is larger than the entire three-star-and-below tail combined. That shape usually indicates a large group of satisfied-but-not-enthusiastic raters rather than a polarised product. All five buckets are rounded whole percentages, so a 1% bucket is a rounded share and not proof that no rater sat there; and with 5,101 ratings a single rating moves any bucket by only about 0.02 percentage points, which means the shape shown above is stable at this sample size rather than noisy.

2.2 What Customers Say

Amazon's generated summary for this listing reads: Customers find the antifungal powder effective, with one noting it works better than baby powder, and they appreciate its ability to keep feet dry and eliminate odor. The value for money receives mixed reviews, with some finding it worth the price while others disagree.

Four aspects carry enough mentions to be broken out, and the pattern is clean. Effectiveness dominates with 169 mentions — nearly three times the other three combined — and is positive in 92% of them. Moisture absorption (97%) and odour reduction (90%) are smaller and nearly unanimous, which matters because those two are the powder's mechanical claims rather than its drug claim. Value for money is the one genuinely contested aspect at 66% positive.

The value-for-money split is worth reading against the price history in section 4. The listing's own all-time price band is wide, and the current three-pack price sits below the list price; a buyer who paid during the 2024 spike would have a materially different view of value than one buying at today's figure. A contested value aspect on a product whose effectiveness is rated at 92% is usually a price perception problem, not a product problem.

2.3 Review Text Availability

No individual United States review text could be captured for this ASIN at collection time. The review page was requested directly, then through a mobile rendering, then through an alternative delivery context, and finally through a three-attempt retry loop with fresh sessions at 15, 30 and 45 second intervals; every response rendered zero review bodies. The aggregate rating, the star histogram and the "Customers say" summary above are all visible on the product page and are reported here, but no review body is quoted anywhere in this report and no reviewer identity is reproduced. The qualitative signal in this section is an Amazon-generated aggregation, and it is labelled as such.

3. Product Ingredients

The panel below is transcribed from the listing's own published ingredient declaration. It is a Drug Facts panel, not a cosmetic INCI declaration: one active pharmaceutical ingredient, followed by five inactive ingredients, six entries in total. That structure is why the ingredient databases consulted in 3.3 behave differently here than they would for a skincare product.

3.1 Full Ingredient List

The listing prints "Corn Starch"; the Skinsort cross-reference in 3.3 carries the same material under its INCI name, Zea Mays Starch. They are one ingredient, counted once.

3.2 Classified by Level

Classifying the six entries by the level at which each operates produces five groups. Unlike a cosmetic panel, this one is dominated by a single functional entry: the active. Everything else exists to carry the active to the skin, keep the area dry, and control odour.

What the classification says

• The panel is short because the format allows it to be. A dry, anhydrous powder needs no preservative system, no emulsifier, no humectant and no fragrance to remain stable. Six entries is a complete formula for this dosage form, and nothing in the panel is present for cosmetic effect except the zinc oxide.
• Two thirds of the inactive panel is absorbency. Corn starch and kaolin together are the moisture-absorbing base, and they are what makes the product a powder rather than a cream or a spray. The "keeps feet dry" claim rests on these two and is directly supported by the aspect table in section 2, where moisture absorption is the highest-scoring aspect at 97%.
• There is no fragrance and no EU-declarable allergen. The absence is structural rather than incidental: the panel has no fragrance entry at all. For a reader who avoids fragrance, this is one of the few foot-care formats where the avoidance is unambiguous.
• Miconazole nitrate is an azole antifungal. It works by inhibiting fungal ergosterol synthesis. The listing's four-week course for athlete's foot and ringworm, and two-week course for jock itch, are consistent with how this class is normally directed. Nothing in this report is a clinical recommendation; the printed directions in section 1.5 are the manufacturer's own.
• Benzethonium chloride is doing double duty. It is an antimicrobial in its own right and is listed second, which in a Drug Facts panel means it is the first inactive by concentration. Its presence alongside the active is what supports the odour-reduction aspect at 90% positive.

3.3 Database Cross-Check: What Was and Was Not Found

Two independent ingredient databases were queried for this ASIN. Neither holds an entry under the listing's exact product name, but one holds a same-brand Lotrimin medicated foot powder whose panel matches the listing's own declaration one-for-one. The audit is recorded in full, because the identity question is the interesting part.

The identity question, stated carefully

The match is strong but not conclusive. On one side: same brand, same format (medicated foot powder), same active at the same 2% strength, and a six-of-six ingredient match in the same order — Benzethonium Chloride, Zea Mays Starch, Kaolin, Sodium Bicarbonate, Zinc Oxide, with corn starch and Zea Mays Starch being the same material under different names. On the other side, the names differ — "AF Athlete's Foot Antifungal Powder" on the listing versus "Athlete's Foot Daily Prevention Medicated Foot Powder" on Skinsort — and Lotrimin does market separate treatment and daily-prevention powders that both carry miconazole nitrate 2%.

This report therefore treats the Skinsort data as a supplementary signal with a disclosed identity caveat. The ingredient analysis in 3.2 rests on the listing's own published panel, which is primary. The claim matrix below is labelled as belonging to the candidate entry, so a reader can weigh the caveat themselves.

3.4 Skinsort Claim Matrix (candidate entry)

Eleven of eleven badges were captured on the full channel. Nine claims hold and two do not.

Two cautions apply to this matrix. First, it describes the candidate entry, not this ASIN by name — the identity caveat in 3.3 carries over. Second, the two negative claims are about the brand's corporate posture rather than the ingredient panel; a reader whose concern is the formula itself should read the nine positive rows and treat the last two as separate information.

One further observation on the Skinsort entry's own claims: its benefits block lists "Good For Oily Skin", "Acne Fighting" and "Reduces Large Pores", which are skincare-mapped readings of starch, clay and zinc. They are reported in the source file for completeness but are not reproduced here as findings, because they have little to do with how a foot powder is used. The entry is also unrated — no community score exists for it.

4. Product Price and Price History

4.1 Price at Capture

The listing was in stock and sold and shipped by Amazon at capture, priced at $20.29 for the three-bottle pack — $2.25 per ounce of product. The list price on record is $23.99, so the current figure runs 15% below list. A Subscribe & Save option was offered at $17.25, which is 28% below the one-time price and is the best unit price visible on the page at $1.92 per ounce.

4.2 Price History Summary

The table below is the all-time price record from an independent Amazon price-tracking source covering this ASIN since November 1, 2020 — about six years. Every figure is an all-time value across that whole window, not a 30-day, 6-month or 12-month statistic. Both current observations are dated one day before this report's capture date.

Every cell of the 3rd Party Used row is a dash: this product has never carried a used offer in six years of monitoring. An OTC antifungal powder is a consumable, not a collectible, and no secondary market for it exists. That is a finding, not a gap.

4.3 Comparing the Two Active Channels

Averaged over the full window, Amazon's own price has run $22.58 and third-party new $20.59, a $1.99 premium for first-party fulfilment. Both current observations are identical at $20.29 — the third party is matching the first party rather than undercutting it, which is what a healthy, fully stocked market looks like. Against the $23.99 list price, the first-party average runs 5.9% under and the third-party average 14.2% under.

4.4 The 2024 Spike Is Not a Price

Both first-party extremes fall inside a single calendar year and only five months apart: a $43.71 high on June 26, 2024 and a $16.79 low on November 28, 2024. A 2.6x collapse inside five months, landing on a Black Friday date, is the signature of a stock-out and recovery cycle rather than a repricing. Two consequences follow, both derivations rather than source figures.

• The $22.58 first-party average is inflated. It is pulled upward by the 2024 spike and should not be read as the normal shelf price. The list price of $23.99 and the current $20.29 are better anchors.
• The $43.71 high is not a meaningful ceiling. It sits 82% above list and has never been approached since. A reader evaluating this product today should anchor on $23.99 and $20.29, not on either 2024 extreme.

The third-party band is much tighter: $10.48 from low to high, a 53.7% spread, with its high dated to December 2021 and never approached since either.

4.5 Where the Current Price Sits

Placed on its own all-time band, today's $20.29 sits 13.0% of the way up the first-party band and 7.3% of the way up the third-party band. It is 20.8% above the first-party all-time low and only 3.9% above the third-party all-time low, which was set ten days before this report was written. In plain terms: this is a normal-to-favourable time to buy. The current price is 15% below list, the Subscribe & Save route is 28% below list, and neither 2024 extreme is relevant to a purchase today.

4.6 Timeline of Dated Extremes

The third-party all-time low of $19.52, dated ten days before capture, is the most informative recent figure in the table: it says the third-party floor has moved up to just under the current first-party price, and that the two channels are now effectively one price.

5. Methodology, Confidence and Limitations

5.1 How This Report Was Built

• Marketplace and context. The product page was read on amazon.com from a United States delivery context (New York 10001). Prices are native USD throughout; no currency conversion was performed and none is implied.
• Ingredient source. The six-entry panel in section 3 is transcribed from the listing's own published Drug Facts declaration. No ingredient list was reconstructed from brand knowledge.
• Cross-checks. Two independent ingredient databases were queried. COSDNA holds nothing for this product. Skinsort holds no page under the listing's name but does hold a same-brand Lotrimin foot powder with a six-of-six panel match; it is used as a disclosed cross-reference with the identity caveat stated, never silently.
• Price history. The all-time record in section 4 comes from an independent price-tracking source that has monitored this ASIN since November 2020, read once with the full-window setting.
• Privacy. No reviewer name, handle, profile identifier, avatar or profile link appears anywhere in this report. No review body is quoted at all for this ASIN, because none could be captured.
• Snapshot discipline. Rank, availability and price move between captures. Everything here describes the state observed on 2026-10-27.

5.2 Confidence by Element

5.3 Limitations

1. All-time price figures only. Period-specific lows, highs and averages are not obtainable from this source. A question such as "what was the lowest price in the last six months" cannot be answered from the data used here.
2. No observation-level price history. Only five values per price type are exposed, so the shape of the 2024 spike and collapse is inferred from two dated endpoints only.
3. No review text. Zero review bodies rendered across every capture strategy tried. The qualitative layer rests on Amazon's own aggregation, which is a weaker evidence class than quoted reviews.
4. No customer photos. The listing exposed no buyer image tiles, so the gallery in section 1 is listing imagery only.
5. No independent ingredient-database entry under this product's own name. The cross-reference rests on a probable same-formula match whose identity cannot be settled from available evidence.
6. Skinsort's skincare-oriented claim model. Its benefits block for the candidate reads as a foot powder being judged by moisturiser criteria; those claims were captured and set aside rather than reproduced as findings.
7. This is a drug, and this report is not medical advice. The active ingredient, concentrations and treatment courses reported here are transcriptions of the manufacturer's own printed material. Nothing in this report is a clinical recommendation.
8. Entry-count percentages are not weight percentages. Saying the absorbent base is 33% of entries says nothing about its share by weight.